IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NEMOTO et al.

Appl. No.: 10/566,573

Int'l Filing Date: July 30, 2004

For: Methods of Screening for Useful

Proteins (as amended)

Confirmation No.: 3545

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 2144.0330000/RWE/RAS

First Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Mail Stop Amendment

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on June 5, 2006 in connection with the above-captioned application.

Copies of documents NPL12 and NPL13 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached IDS Forms are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert A. Schwartzman, Ph.D.

Agent for Applicants Registration No. 50,211

Date: September 5, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 577559_1.DOC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO | Complete | Complete if Known | | |
|-----------------------------------|-----------------------------|----------------------|--|--|
| THE COP CITION TO A TRACE A T | Application Number | 10/566,573 | | |
| FIRST SUPPLEMENTAL | Int'l Filing Date | July 30, 2004 | | |
| INFORMATION DISCLOSURE | i Trist Ivallied illyclikol | Naoto Nemoto | | |
| STATEMENT BY APPLICANT | Art Unit | To Be Assigned | | |
| (Use as many sheets as necessary) | Examiner Name | To Be Assigned | | |
| Sheet 1 of 1 | Attorney Docket Number | 2144.0330000/RWE/RAS | | |

| | | | U.S. PATENT DO | OCUMENTS | | |
|---------------------------------|------|--|------------------|-----------------------------|--|--|
| Examiner Cite Initials No. 1 | | Document Number | Publication Date | Name of Patentee or | Pages, Columns, Lines, | |
| | No.' | Number-Kind Code ^{2 (If Known)} | MM-DD-YYYY | Applicant of Cited Document | Where Relevant Passages or Relevant Figures Appear | |
| | US1 | 2003/0113835 A1 | 06-19-2003 | Imamura <i>et al</i> . | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | <u> </u> | | |
| | US | | | | | |
| | US | | | | . | |
| | US | | | | | |
| | US | | | | | |
| | US | 1 | | | | |
| | US | | | | | |
| | US | ļ <u>.</u> | | | | |
| | US | | | | | |
| | US | | | | | |
| | US | | | | | |

| | | Fo | REIGN PATENT DO | CUMENTS | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |
| | FP | | | | | |

577548 1.DOC

| Examiner | Date | · |
|-----------|------------|---|
| Signature | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO | | Complete if Known | | | |
|--|---|-------------------|----------------|------------------------|----------------------|
| EUDCT CUIDDI ENVENTE AT | | | PAT | Application Number | 10/566,573 |
| FIRST SUPPLEMENTAL | | Int'l Filing Date | July 30, 2004 | | |
| INFORMATION DISCLOSURE | | | | First Named Inventor | Naoto NEMOTO |
| STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Art Unit | To Be Assigned | | |
| | | Examiner Name | To Be Assigned | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 2144.0330000/RWE/RAS |

| | · · · · · | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|--|-----------------------|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published | T ² |
| | NPL12 | Miyamoto-Sato, E., et al., "Specific bonding of puromycin to full-length protein at the C-terminus", Nucleic Acids Res. 28:1176-1182, Oxford University Press (2000) | |
| | NPL13 | Copy of European Search Report, European Patent Office, Munich, mailed August 1, 2006 | |
| | | | |
| | | | |
| | | | 0 0 0 0 0 |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| 577554_ | 1.DOC | ·· · · · · · · · · · · · · · · · · · · | |
| Examiner | Τ. | Date | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including asthering asserting and submitting the completed explication form to the USPTO. Time will use a depend on the included application. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.